Search results for "VENOUS THROMBOSIS"

showing 10 items of 183 documents

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.

2021

Non-cirrhotic portal vein thrombosis (PVT) in patients with antiphospholipid syndrome (APS) is a rare complication, and the management has to be determined individually based on the extent and severity of the presentation. We report on a 37-year-old male patient with non-cirrhotic chronic PVT related to a severe thrombophilia, comprising APS, antithrombin-, factor V- and factor X-deficiency. Three years after the initial diagnosis of non-cirrhotic PVT, the patient presented with severe hemorrhagic shock related to acute bleeding from esophageal varices, requiring an emergency transjugular intrahepatic portosystemic stent shunt (TIPSS). TIPSS was revised after a recurrent bleeding episode du…

AdultMalemedicine.medical_specialtyPortal venous pressuremedicine.medical_treatment030204 cardiovascular system & hematologyThrombophiliaEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalmedicineHumansThrombophiliaEmbolizationPatient Care TeamVenous Thrombosisbusiness.industryPortal VeinGastroenterologymedicine.diseaseThrombosisSurgeryPortal vein thrombosisPortal hypertension030211 gastroenterology & hepatologyStentsPortasystemic Shunt Transjugular IntrahepaticbusinessVaricesGastrointestinal HemorrhageZeitschrift fur Gastroenterologie
researchProduct

Acute symptomatic seizures in cerebral venous thrombosis

2020

© 2020 American Academy of Neurology

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageInfarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineModified Rankin ScaleRisk FactorsSeizuresInternal medicinemedicineHumans030212 general & internal medicineStrokeIntracerebral hemorrhageVenous Thrombosisbusiness.industrycerebral venous thrombosisSymptomatic seizuresOdds ratioMiddle Agedmedicine.diseaseThrombosisCerebral Veins3. Good healthVenous thrombosisAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)Intracranial Thrombosisbusiness030217 neurology & neurosurgery
researchProduct

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Usefulness of Thrombophilia Testing in Venous Thromboembolic Disease

2012

Information on thrombophilia risk factors for patients with upper extremity deep vein thrombosis (UEDVT) is limited. The genetic, acquired, and coagulation risk factors of an acute episode of lower EDVT (LEDVT) or UEDVT, either isolated or associated with pulmonary embolism (PE), were studied.A total of 4503 patients participated in a thrombophilia study. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated.Mean age of the participants was 55 ± 19 years. The risk of LEDVT or UEDVT, isolated or associated with PE, was calculated according to thrombophilia factors. We found association between LEDVT and factor V Leiden ([FVL]; OR: 1.8; 95% CI 1.4-2.4) and resistance to activated…

AdultMalemedicine.medical_specialtyThrombophiliaRisk FactorsInternal medicinemedicineFactor V LeidenHumansThrombophiliaUpper Extremity Deep Vein ThrombosisRegistriesActivated Protein C ResistanceAgedVenous Thrombosisbusiness.industryAge FactorsFactor VVenous ThromboembolismHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalSurgeryPulmonary embolismProthrombin G20210AFemaleProthrombinbusinessProtein CFollow-Up Studiesmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

[Inferior vena cava malformations and deep venous thrombosis].

2006

We carried out a prospective study of 116 patients under 50 years of age who had deep venous thrombosis of the lower extremities to determine whether the presence of congenital anomaly of the inferior vena cava (IVC) was a risk factor for the disease. All patients were investigated by Doppler echography. Some 37 patients who had iliac vein occlusion also underwent phlebography. In 10 patients in whom the IVC was difficult to image, magnetic resonance angiography or computerized axial tomography was carried out. In all patients, studies of antithrombin, protein C and protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, and acquired risk factors were also p…

AdultMalemedicine.medical_specialtyTime FactorsPopliteal VeinFemoral veinVena Cava InferiorIliac VeinInferior vena cavaRecurrenceRisk FactorsmedicineFactor V LeidenConfidence IntervalsHumansProtein S deficiencyProspective StudiesVenous ThrombosisLegbusiness.industryAnticoagulantsUltrasonography DopplerGeneral MedicinePhlebographyFemoral VeinMiddle Agedmedicine.diseaseThrombosisVein occlusionSurgeryVenous thrombosisTreatment Outcomemedicine.veincardiovascular systemProthrombin G20210AFemaleRadiologybusinessTomography X-Ray ComputedMagnetic Resonance AngiographyFollow-Up StudiesRevista espanola de cardiologia
researchProduct

Dose-Adjusted Thrombosis Prophylaxis in Trauma Surgery According to Levels of D-Dimer

2000

In 234 trauma surgery patients, thrombosis prophylaxis with Nadroparin-Calcium low-molecular-weight heparin (LMWH) was adjusted according to levels of D-Dimer. Basic prophylaxis was 2,850 IU per day. If D-Dimer concentrations rose above 2 mg/L after the fourth postoperative (p.o.) day, LMWH was administered twice a day. Color Doppler ultrasound was performed between the fifth and seventh p.o. days. Patients were divided into a high-risk (group 1: hip, femur, or knee replacement surgery, n=102) and a moderate-risk group (group 2: other surgery of the knee, tibia, fibula, or foot, n=132). Group 1 showed significantly higher D-Dimer levels than group 2 (p0.001). Measurement of D-Dimer on days …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentDeep veinAntithrombin IIIKnee replacementLow molecular weight heparinSensitivity and SpecificityFibrin Fibrinogen Degradation ProductsFractures BoneRisk FactorsAntifibrinolytic agentD-dimerHumansMedicineAgedAged 80 and overVenous Thrombosisbusiness.industryAnticoagulantNadroparinHematologyMiddle Agedmedicine.diseaseAntifibrinolytic AgentsSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiaWounds and InjuriesFemalebusinessTrauma surgeryBiomarkersLeg InjuriesPeptide HydrolasesThrombosis Research
researchProduct

Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis.

2018

Lemierre syndrome usually affects otherwise healthy adolescents or young adults and occurs at an overall rate of 1 to 10 cases per million person-years with an estimated fatality rate of 4 to 9%. Diagnostic criteria remain debated and include acute neck/head bacterial infection (often tonsillitis caused by anaerobes at high potential for sepsis and vascular invasion, notably Fusobacterium necrophorum) complicated by local vein thrombosis, usually involving the internal jugular vein, and systemic septic embolism. Medical treatment is based on antibiotic therapy with anaerobic coverage, anticoagulant drugs and supportive care in case of sepsis. Surgical procedures can be required, including d…

AdultMalemedicine.medical_specialtyTonsillitisved/biology.organism_classification_rank.species030204 cardiovascular system & hematologySepsis03 medical and health sciencesYoung Adult0302 clinical medicineFusobacterium necrophorumJugular veinCase fatality ratemedicineHumansIntensive care medicine610 Medicine & healthInternal jugular veinSeptic embolismVenous Thrombosisbusiness.industryved/biologyAnticoagulantsHematologyLemierre Syndromemedicine.diseaseLemierre Study GroupPrognosisAnti-Bacterial AgentsVenous thrombosisFusobacterium necrophorumbusiness030215 immunologyHamostaseologie
researchProduct

Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis.

2019

Multiple studies have shown that in approximately half of individuals with pulmonary embolism (PE), the deep venous thrombosis (DVT) is not evident at the moment of PE diagnosis. The underlying factors and the origin of PE in these patients are not completely understood: missed DVT, embolization of DVT in its entirety, or de-novo PE being possible explanations. The aim of this study was to evaluate the differences in PE patient with or without co-existing DVT. Sixty-three consecutive PE patients were included. Whole leg bilateral Doppler compression ultrasound was performed to all patients. The PE location and extension, C-reactive protein, platelet count, hemostatic markers FV, FVIII, FXII…

AdultMalemedicine.medical_specialtyVEIN THROMBOSISmedicine.medical_treatment030204 cardiovascular system & hematologyFibrinogenPulmonary function testing03 medical and health sciencesTHROMBOEMBOLISM0302 clinical medicineInternal medicineSCOREmedicineFactor V LeidenFACTOR-V-LEIDENHumanscardiovascular diseasesEmbolizationProspective Studiescoagulationhemostatic markersProspective cohort studydeep venous thrombosisAgedRISKVenous ThrombosisHemostasisLegbusiness.industryUltrasonography DopplerHematologyGeneral MedicineNITRIC-OXIDE MEASUREMENTSMiddle Agedmedicine.disease3. Good healthPulmonary embolismVenous thrombosis3121 General medicine internal medicine and other clinical medicineHemostasisisolated pulmonary embolismCardiologyFemalebusinessPulmonary Embolism030215 immunologymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct